Literature DB >> 26791866

Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk.

Mark I Travin1, Milena J Henzlova2, Berthe L F van Eck-Smit3, Diwakar Jain4, Ignasi Carrió5, Russell D Folks6, Ernest V Garcia6, Arnold F Jacobson7,8, Hein J Verberne3.   

Abstract

RATIONALE: 123I-mIBG planar image heart-to-mediastinum ratios effectively risk-stratify heart failure (HF) patients. The value of single-photon emission computed tomographic (SPECT) imaging for identifying increased risk of ventricular arrhythmias is less clear. This study sought to determine if findings from simultaneous interpretation of 123I-mIBG and 99mTc-tetrofosmin SPECT are predictive of arrhythmic events (ArEs).
METHODS: 123I-mIBG SPECT images from 622 patients with ischemic HF were presented in standard displays alongside 99mTc-tetrofosmin images. Consensus interpretations using a 17-segment model produced summed scores. Cox proportional hazards analyses related findings to adjudicated ArEs over 2 years.
RESULTS: 471 patients had images adequate for total 17-segment scoring. There were 48 ArEs (10.2%). Neither 123I-mIBG nor 99mTc-tetrofosmin SPECT summed scores were univariate predictors. On multivariate proportional hazards analysis, the 123I-mIBG SPECT score was independently predictive of ArEs (HR: 0.975, 95% CI 0.951-0.999, P = 0.042), but HR<1 indicated that risk decreased with increasing score. This occurred because patients with intermediately abnormal SPECT studies had a higher likelihood of ArEs compared to patients with extensive abnormalities.
CONCLUSIONS: The presumption of a monotonic increase in ArE risk with increasing summed 123I-mIBG SPECT score may not be correct as ischemic HF patients with abnormalities of intermediate extent appear at highest risk.

Entities:  

Keywords:  123I-mIBG; SPECT; arrhythmias; heart failure

Mesh:

Substances:

Year:  2016        PMID: 26791866     DOI: 10.1007/s12350-015-0336-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  32 in total

1.  I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator.

Authors:  Rishi Arora; Kevin J Ferrick; Tomoaki Nakata; Robert C Kaplan; Michael Rozengarten; Farhana Latif; Kaman Ng; Vanessa Marcano; Sherman Heller; John D Fisher; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: The ADMIRE-HFX Study.

Authors:  Jagat Narula; Myron Gerson; Gregory S Thomas; Manuel D Cerqueira; Arnold F Jacobson
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

4.  Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure.

Authors:  Amil M Shah; Mikhail Bourgoun; Jagat Narula; Arnold F Jacobson; Scott D Solomon
Journal:  JACC Cardiovasc Imaging       Date:  2012-11

5.  Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction.

Authors:  Tetsuo Sasano; M Roselle Abraham; Kuan-Cheng Chang; Hiroshi Ashikaga; Kevin J Mills; Daniel P Holt; John Hilton; Stephan G Nekolla; Jun Dong; Albert C Lardo; Henry Halperin; Robert F Dannals; Eduardo Marbán; Frank M Bengel
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

6.  Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application.

Authors:  J D Minardo; M M Tuli; B H Mock; R E Weiner; H P Pride; H N Wellman; D P Zipes
Journal:  Circulation       Date:  1988-10       Impact factor: 29.690

7.  Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction.

Authors:  Marcus V Simões; Petra Barthel; Ichiro Matsunari; Stephan G Nekolla; Albert Schömig; Markus Schwaiger; Georg Schmidt; Frank M Bengel
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

8.  123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials.

Authors:  Arnold F Jacobson; John Lombard; Gopa Banerjee; Paolo G Camici
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

9.  A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.

Authors:  Tomoaki Nakata; Kenichi Nakajima; Shohei Yamashina; Takahisa Yamada; Mitsuru Momose; Shu Kasama; Toshiki Matsui; Shinro Matsuo; Mark I Travin; Arnold F Jacobson
Journal:  JACC Cardiovasc Imaging       Date:  2013-07

10.  Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction.

Authors:  A I McGhie; J R Corbett; M S Akers; P Kulkarni; M N Sills; M Kremers; L M Buja; M Durant-Reville; R W Parkey; J T Willerson
Journal:  Am J Cardiol       Date:  1991-02-01       Impact factor: 2.778

View more
  18 in total

1.  Assessing arrhythmic risk with 123I-mIBG and analogous tracers: Image interpretation from a different viewpoint.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2017-07-05       Impact factor: 5.952

Review 2.  Current Clinical Applications and Next Steps for Cardiac Innervation Imaging.

Authors:  Mark I Travin
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

3.  Phase dyssynchrony and 123I-meta-iodobenzylguanidine innervation imaging towards standardization.

Authors:  Kenichi Nakajima; Koichi Okuda; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2017-09-18       Impact factor: 5.952

4.  What future for the myocardial sympathetic innervation imaging?

Authors:  Federico Caobelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12       Impact factor: 9.236

Review 5.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2017. Part 1 of 2: Positron emission tomography, computed tomography, and magnetic resonance.

Authors:  Wael A AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-11-08       Impact factor: 5.952

Review 6.  Structural and Physiological Imaging to Predict the Risk of Lethal Ventricular Arrhythmias and Sudden Death.

Authors:  Saurabh Malhotra; John M Canty
Journal:  JACC Cardiovasc Imaging       Date:  2019-10

Review 7.  Cardiac 123I-mIBG Imaging in Heart Failure.

Authors:  Derk O Verschure; Kenichi Nakajima; Hein J Verberne
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

8.  Positron Emission Tomography Imaging of Regional Versus Global Myocardial Sympathetic Activity to Improve Risk Stratification in Patients With Ischemic Cardiomyopathy.

Authors:  Jason G E Zelt; Jean Zhuo Wang; Lisa M Mielniczuk; Rob S B Beanlands; James A Fallavollita; John M Canty; Robert A deKemp
Journal:  Circ Cardiovasc Imaging       Date:  2021-06-09       Impact factor: 8.589

9.  Quality and utility of [123I]I-metaiodobenzylguanidine cardiac SPECT imaging in nondiabetic postinfarction heart failure patients qualified for implantable cardioverter defibrillator.

Authors:  Anna Teresińska; Olgierd Woźniak; Aleksander Maciąg; Jacek Wnuk; Jarosław Jezierski; Aneta Fronczak; Elżbieta Katarzyna Biernacka
Journal:  Ann Nucl Med       Date:  2021-05-23       Impact factor: 2.668

Review 10.  Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation.

Authors:  D O Verschure; B L F van Eck-Smit; G A Somsen; R J J Knol; H J Verberne
Journal:  Neth Heart J       Date:  2016-12       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.